or Try an Advanced Search...

    Technical Analysis for CGON - CG Oncology, Inc.

    Grade Last Price % Change Price Change
    F 32.80 1.74% 0.56
    CGON closed down 1.71 percent on Wednesday, November 20, 2024, on 87 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CGON trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 1.74%
    Lower Bollinger Band Touch Weakness 1.74%
    Oversold Stochastic Weakness 1.74%
    Doji - Bullish? Reversal 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Jack-in-the-Box Bearish Bearish Swing Setup -1.23%
    Lower Bollinger Band Walk Weakness -1.23%
    Inside Day Range Contraction -1.23%
    Older End-of-Day Signals for CGON ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 1 hour ago
    Outside Day about 1 hour ago
    Up 2% about 1 hour ago
    60 Minute Opening Range Breakout about 2 hours ago
    Up 1% about 2 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CGON Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus

    Is CGON a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
    Nov 14 CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 12 CG Oncology, Inc. GAAP EPS of -$0.30
    Nov 12 CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
    Nov 11 CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
    Oct 21 Top small-cap stock picks from Morgan Stanley following the group's upgrade to neutral
    Oct 1 We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth
    Sep 16 CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data
    Sep 14 Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock
    Aug 30 CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    See more CGON news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 50.23
    52 Week Low 25.77
    Average Volume 632,449
    200-Day Moving Average 36.37
    50-Day Moving Average 36.45
    20-Day Moving Average 36.20
    10-Day Moving Average 35.75
    Average True Range 1.75
    RSI (14) 33.77
    ADX 18.35
    +DI 13.98
    -DI 31.71
    Chandelier Exit (Long, 3 ATRs) 35.23
    Chandelier Exit (Short, 3 ATRs) 36.77
    Upper Bollinger Bands 40.50
    Lower Bollinger Band 31.89
    Percent B (%b) 0.04
    BandWidth 23.77
    MACD Line -0.87
    MACD Signal Line -0.23
    MACD Histogram -0.6324
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 34.53
    Resistance 3 (R3) 34.55 33.80 34.15
    Resistance 2 (R2) 33.80 33.22 33.79 34.02
    Resistance 1 (R1) 33.02 32.86 32.65 33.00 33.89
    Pivot Point 32.28 32.28 32.09 32.27 32.28
    Support 1 (S1) 31.50 31.69 31.12 31.48 30.59
    Support 2 (S2) 30.75 31.33 30.74 30.46
    Support 3 (S3) 29.97 30.75 30.33
    Support 4 (S4) 29.95